A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer

Fang Wan, Xin Chen, Li-Fan Dong, Yue-Hong Cheng, Jing-Pei Long *

Abstract

**Background:** This systemic analysis was conducted to evaluate the efficacy and safety of pemetrexed based chemotherapy in treating patients with metastatic breast cancer as first or second line chemotherapy. **Methods:** Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with breast cancer were identified using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. **Results:** In first line pemetrexed based regimens, 10 clinical studies which including 513 patients with advanced breast cancer were considered eligible for inclusion. For second line pemetrexed based chemotherapy, 5 clinical studies which including 281 patients with advanced breast cancer were considered eligible. Systemic analysis suggested that, in all patients, pooled RR was 32.6 % (167/513) in pemetrexed based first line regimens, and 13.9 % (39/281) in pemetrexed based second line regimens. **Conclusion:** This systemic analysis suggests that pemetrexed based first line regimens are associated with a reasonable response rate and acceptable toxicity, however with low response rate when is used in the second line.

Keywords: Pemetrexed - breast cancer

Asian Pac J Cancer Prev, 15 (11), 4567-4570

Introduction

The incidence and mortality rate of breast cancer increased significantly in China over the last several decades (Yu et al., 2007). It was estimated that 121,269 new cases of breast cancer were diagnosed in China in 2000 and 168,013 in 2005 (Yang et al., 2005). Despite advances in prevention, risk factor reduction, early diagnosis and treatment, breast cancer remains a main public health concern, with more than a million new cases diagnosed annually, resulting in >400,000 deaths worldwide (Ferlay et al., 2002; Huang et al., 2004).

Now, combined chemotherapy is mostly prescribed in neoadjuvant, adjuvant and in metastatic settings of breast cancer. Although CMF regimen represented the gold standard in the 1970s (Bonadonna et al., 1976), anthracycline-based regimens are the mainstay of adjuvant chemotherapy for early breast cancer since the 1990s (EBCTCG, 2005). When single-agent chemotherapy was used in hormone-resistant metastatic setting, agents considered to be active include cyclophosphamide, phenylalanine mustard, vincristine, vinblastine, methotrexate and 5-fluorouracil. Response rates are ranged from 0-38% (Akram et al., 2012). Pemetrexed has been tested in five phase II trials in locally advanced or metastatic breast cancer, and has shown an activity of around 30% in advanced breast cancer patients with minimal or no prior chemotherapy. In patients who received prior anthracyclines, response rates of 21% were reported. Responses have also been observed in patients who had been pretreated with anthracyclines, taxanes, and capecitabine. Some studies have suggested that a correlation exists between thymidylate synthase tumor expression with pemetrexed antitumor activity; this attractive hypothesis should be confirmed in further studies (Martin, 2006).

Robert NJ et al reported a subset analysis of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Based on 35 evaluable patients, the overall response rate (ORR) was 26% (1 CR and 8 PR), and the clinical benefit rate (CR+PR+ stable disease [SD] ≥ 6 months) was 40%. Median progression-free survival (PFS) was 4.1 months (range, <1-22.4). Median overall survival (OS) was 18.9 months (range, <1-27.7). Grades 3-4 treatment-related toxicities included: neutropenia (36%), leukopenia (17%), fatigue (14%), and anemia (14%). Grade 1/2 alopecia was seen in 8% of patients (Robert et al., 2011).

Garin A et al reported a subset analysis of a phase II study with pemetrexed and carboplatin in patients with advanced or metastatic breast cancer, and has shown an activity of around 30% in advanced breast cancer patients with minimal or no prior chemotherapy. In patients who received prior anthracyclines, response rates of 21% were reported. Responses have also been observed in patients who had been pretreated with anthracyclines, taxanes, and capecitabine. Some studies have suggested that a correlation exists between thymidylate synthase tumor expression with pemetrexed antitumor activity; this attractive hypothesis should be confirmed in further studies (Martin, 2006).

Robert NJ et al reported a subset analysis of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Based on 35 evaluable patients, the overall response rate (ORR) was 26% (1 CR and 8 PR), and the clinical benefit rate (CR+PR+ stable disease [SD] ≥ 6 months) was 40%. Median progression-free survival (PFS) was 4.1 months (range, <1-22.4). Median overall survival (OS) was 18.9 months (range, <1-27.7). Grades 3-4 treatment-related toxicities included: neutropenia (36%), leukopenia (17%), fatigue (14%), and anemia (14%). Grade 1/2 alopecia was seen in 8% of patients (Robert et al., 2011).

Garin A et al reported a subset analysis of a phase II study with pemetrexed and carboplatin in patients with advanced or metastatic breast cancer, and has shown an activity of around 30% in advanced breast cancer patients with minimal or no prior chemotherapy. In patients who received prior anthracyclines, response rates of 21% were reported. Responses have also been observed in patients who had been pretreated with anthracyclines, taxanes, and capecitabine. Some studies have suggested that a correlation exists between thymidylate synthase tumor expression with pemetrexed antitumor activity; this attractive hypothesis should be confirmed in further studies (Martin, 2006).

Robert NJ et al reported a subset analysis of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Based on 35 evaluable patients, the overall response rate (ORR) was 26% (1 CR and 8 PR), and the clinical benefit rate (CR+PR+ stable disease [SD] ≥ 6 months) was 40%. Median progression-free survival (PFS) was 4.1 months (range, <1-22.4). Median overall survival (OS) was 18.9 months (range, <1-27.7). Grades 3-4 treatment-related toxicities included: neutropenia (36%), leukopenia (17%), fatigue (14%), and anemia (14%). Grade 1/2 alopecia was seen in 8% of patients (Robert et al., 2011).
locally advanced or metastatic breast cancer. Partial responses (RECIST criteria) were achieved in 27 (54.0%) patients (ORR = 54.0%; 95% CI, 39.3-68.2%). The median response duration was 11.1 months (95% CI, 6.5-14.0 months) and the median time to disease progression was 10.3 months (95% CI, 8.3-14.6 months). CTC haematologic toxicities were grade 3/4 neutropenia (58.0%/28.0%) and grade 3 thrombocytopenia (10.0%) and anaemia (18.0%). Two (4.0%) patients had febrile neutropenia, 1 of whom died. No grade 4 non-haematologic toxicities occurred.

Grade 3 non-haematologic toxicities were ALT (4.0%) and AST elevation, and edema, fatigue, pruritus, rash/desquamation, and renal toxicity (2.0% each) (Garin et al., 2008).

According to this background, we hypothesize that pemetrexed originated regimen could be established as an optimal schedule for patients with advanced breast cancer.

Materials and Methods

Search strategy

We searched PUBMED, by using the following search term: (breast cancer) and (pemetrexed). All clinical studies evaluating the impact of pemetrexed on the response or survival and side effects for breast cancer published in English prior to May 1st of 2014 were identified. If samples of two studies overlap, only the latest one was included. Additional articles were obtained from references within the articles identified by the electronic search. We did not consider meeting abstracts or unpublished reports.

Inclusion and exclusion criteria

We reviewed abstracts of all citations and retrieved studies. The following criteria were used to include published studies: (1) clinical studies, combined with gemcitabine, epirubicine or a platinum; (2) The study was performed in accordance with the Helsinki Declaration (1964, amended in 1975 and 1983) of the World Medical Association. Eligibility criteria included histologically or cytologically verified metastatic and/or locally advanced breast cancer, the presence of at least one bidimensionally measurable lesion, a performance status (WHO) 2, age 18 years. Studies were excluded if one of the following existed: (1) duplicate data; (2) no sufficient data were reported.

Data collection and analysis

Selection of trials and data extraction: The titles and abstracts of publications identified according to the above search strategy were assessed independently for inclusion by two authors, the full text was selected for further assessment if the abstract suggests relevance. Disagreement was resolved by discussion. Data was extracted by independent authors. The following recorded data were extracted: author, publication data, and country of the first or corresponding author, the number of patients.

Results

There were 114 papers relevant to the search words by the end of April, 2014. Via steps of screening the title and reading the abstract, 10 studies were identified (Amadori D 2013; Dittrich C 2012; Robert NJ 2011; Martin M. 2009; Paridaens R 2007; Garin A 2008; Llombart-Cussac A 2007; Ma CX 2006) when pemetrexed was in first line chemotherapy, and 5 in second line chemotherapy (Spielmann M 2001; O'Shaughnessy JA 2005; Deng QQ 2013; Llombart-Cussac A 2006; Martin M 2003). These studies had been carried out in China, Europe countries, and the United States. The following outcomes were presented in at least all studies and extracted for combined analysis: response rate, including the rate of complete or partial response (CR or PR) and toxicities.

Characteristics of pemetrexed as first line chemotherapy, studies included in this study are presented as short-term outcomes: the response rate of Amadori et al. was 26.60%, of Dittrich et al. was 19.1% and 32.8%, of Robert et al. was 26%, of Martin et al. was 56%, of Paridaens et al. was 32%, of Garin et al. was 54%, of Llombart-Cussac A was 17% and 15.6%. Totally, 513 patients were enrolled and 167 patients achieved CR or PR, the pooled response rate thus was 167/513 (32.6%).

When pemetrexed was used in second line chemotherapy, 5 studies included in this study are presented and the short-term outcomes suggested that the response rate of Deng et al. (2013) was 15.8%, of Llombart-Cussac A et al. was 9%, of O'Shaughnessy et al. was 8%, of Martin et al. was 21%, and of Spielmann et al. (2001) was 26%. Totally, 513 patients were enrolled and 167 patients achieved CR or PR, the pooled response rate thus was 39/281 (13.9%). Observation on toxicities: major adverse effects were hematological toxicities, gastrointestinal disturbance, and neurosensory toxicity.

Discussion

Breast cancer remains a significant problem for global health as it is one of the most common cause of tumor-related death worldwide (Fouz et al., 2013; Engin et al., 2013; Sedighi et al., 2013; Zhu et al., 2013; Wu et al., 2014; Cabuk et al., 2014; Chin et al., 2014; Fouladi et al., 2014; Majeed et al., 2014; Gogia et al., 2014; Liu et al., 2014; Louisa et al., 2014; Moazzemy et al., 2014; Niu et al., 2014; Rizalar et al., 2014; Sipetic-Grujicic et al., 2014; Prajoko et al., 2014; Inanc et al., 2014; Varol et al., 2014; Yadav et al., 2014). Pemetrexed is a novel multitargeted antifolate that inhibits several enzymes in the de novo pathways of pyrimidine and purine biosynthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed demonstrated activity in a variety of tumor types based on previous reports, including non-small cell lung cancer, malignant pleural mesothelioma, pancreas, colorectal, gastric, bladder, breast, and head and neck cancers (Martin, 2006).

Pemetrexed has been tested by previous phase II trials in locally advanced or metastatic breast cancer patients and shown an activity of around 30% in advanced breast cancer patients with minimal or no prior chemotherapy. In patients who received prior anthracyclines, response rates of 21% were reported. Responses were also observed in patients who had been pretreated with anthracyclines,
taxanes, and capecitabine. Some studies suggested that a correlation could exist between thymidylate synthase tumor expression with pemetrexed antitumor activity (Martin, 2006); and this hypothesis is supported by this current study.

The main toxicities of pemetrexed are myelosuppression, skin rash, and mucositis. Addition of folic acid and vitamin B12 significantly reduced the toxicity of pemetrexed, especially hematologic toxicity and gastrointestinal toxicity. Pemetrexed is the expected agent for use in high risk patients, especially elderly or poor performance status patients (Sudoh et al., 2008). Hematological toxicity was considerable, and thrombocytopenia was the most prominent toxicity. Nadirs of blood counts were observed between days 14 and 16 after lobaplatin administration. The majority of patients experienced grade 4 thrombocytopenia (Jan Welink et al., 1999). The count of leukocyte and platelet returned to normal after the treatment of colony-stimulating factor, interleukin 11 and recombinant human thrombopoietin.

From previous study, digestive tract reaction ranged from 1 to 2 could be alleviated by symptomatic treatment. By hepatoprotective drugs, transaminase could return to normal. For patients had oral mucositis, with the supplements of vitamins and oral care, the oral mucosal healing with no fungal infection. I patient had rash with pruritis, rash subsided gradually after symptomatic treatment of the antipruritic and anti allergic.

In conclusion, this systemic analysis suggests that pemetrexed based first line regimens are associated with reasonable response rate and accepted toxicities, however with low response rate for treating patients with metastatic breast cancer when it is used in the second line. Future studies with a randomized controlled group are needed to further evaluate the efficacy and tolerability of pemetrexed in this setting.

References

Akrum M, Siddiqui SA (2012). Breast cancer management: Past, present and evolving. Breast Mini Symposium, 49, 277-282.
Bonadonna G, Brusamolino E, Valagussa P, et al (1976). Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med, 294, 405-10.
Cubuk D, Basaran G, Teomete M, et al (2014). Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience. Asian Pac J Cancer Prev, 15, 117-22.
Chin SN, Green CM, Gordon-Strachan GM, et al (2014). Locally advanced breast cancer in Jamaica: prevalence, disease characteristics and response to preoperative therapy. Asian Pac J Cancer Prev, 15, 3323-6.

Early Breast Cancer Trials’ Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687-717.
Engin H, Bilir C, Tekin IO (2013). Prognostic significance of peripheral blood flow cytometry parameters in patients with non-metastatic breast cancer. Asian Pac J Cancer Prev, 14, 7645-9.

Ferlay J, Bray F, Pisani P, et al (2004). Globocan 2002: Cancer incidence, mortality and prevalence worldwide, Version 2.0. IARC Cancer Base No. 5. Lyon, France: IARC Press.
Fouladi N, Ali-Mohammadi H, Pourfarzi F, et al (2014) Exploratory study of factors affecting continuity of cancer care: Iranian Women’s perceptions. Asian Pac J Cancer Prev, 15, 133-7.
Garin A, Manikhas A, Biakhov M, et al (2008). A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat, 110, 309-15.
Huang XE, Hirose K, Wakai K, et al (2004). Comparison of lifestyle risk factors by family history for gastric,breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
Majeed W, Aslam B, Javed I, et al (2014). Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev, 15, 3353-8.
Martin M (2006). Clinical experience with pemetrexed in breast cancer. Semin Oncol, 33, S15-8.
Fouz N, Amid A, Hashim YZ (2013). Cytokinetic study of MCF-7 cells treated with commercial and recombinant bromelain. Asian Pac J Cancer Prev, 14, 6709-14.
Gogia A, Raina V, Deo SV, et al (2014). Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev, 15, 1989-92.
Liu XH, Man YN, Wu XZ (2014). Recurrence season impacts the survival of epithelial ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1627-32.
Louisa M, Soediro TM, Suyatna FD (2014). In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. Asian Pac J Cancer Prev, 15, 1639-42.
Moazzzezy N, Farahany TZ, Olomu M, et al (2014). Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev, 15, 1685-8.
Niu HY, Niu CY, Wang JH, et al (2014). Health-related quality of life in women with breast cancer: a literature-based review of psychometric properties of breast cancer-specific measures. Asian Pac J Cancer Prev, 15, 3533-6.
Rizalar S, Ozbas A, Akyolcu N, et al (2014). Effect of perceived social support on psychosocial adjustment of Turkish patients with breast cancer. Asian Pac J Cancer Prev, 15, 3429-34.
Robert NJ, Conkling PR, O’Rourke MA, et al (2011). Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat, 126, 101-8.
Sipetic-Grujicic SB, Murtezani ZH, Neskovic-Konstatinovic ZB, et al (2014). Multivariate analysis of prognostic factors in male breast cancer in Serbia. Asian Pac J Cancer Prev, 15, 3233-8.
Prajoko YW, Aryanonto T (2014). Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer. Breast Cancer Res Treat, 15, 595-8.
Varol U, Yildiz I, Alacacioglu A, et al (2014). Anticancer therapy for breast cancer patients with skin metastases refractory to conventional treatments. Asian Pac J Cancer Prev, 15, 1885-7.
Inanc M, Duran AO, Karaca H, et al (2014). Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. Asian Pac J Cancer Prev, 15, 253-6.
Sedighi A, Hamed EA, Mohammadian K, et al (2013). Clinicopathologic characteristics of male breast cancer: a report of 21 cases in radiotherapy center of Hamedan, Iran. Asian Pac J Cancer Prev, 14, 7381-3.
Fang Wan et al

Wu LZ, Han RQ, Zhou JY, et al (2008). Incidence and mortality of female breast cancer in Jiangsu, China. Asian Pac J Cancer Prev, 15, 2727-32.

Yadav D, Anwar MF, Garg V, et al (2014). Development of polymeric nanopaclitaxel and comparison with free paclitaxel for effects on cell proliferation of MCF-7 and B16F0 carcinoma cells. Asian Pac J Cancer Prev, 15, 2335-40.

Yang L, Parkin DM, Ferlay J, et al (2005). Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 14, 243-50.

Yu KD, Di GH, Wu J, et al (2007). Development and trends of surgical modalities for breast cancer in China: A review of 16-year data. Ann Surg Oncol, 14, 2502-9.

Zhu ZL, Zhang J, Chen ML, et al (2013). Efficacy and safety of trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. Asian Pac J Cancer Prev, 14, 7111-6.